DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Peripheral T-Cell Lymphoma (PTCL)” report has been
added to ResearchAndMarkets.com’s offering.
This Market Spotlight report covers the Peripheral T-Cell Lymphoma
market, comprising key marketed and pipeline drugs, clinical trials,
upcoming events, probability of success, patent information, a 10-year
disease incidence forecast, and licensing and acquisition deals, as well
as presenting drug-specific revenue forecasts
Key Takeaways
- The author estimates that in 2017, there were approximately 19,950
incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and
forecasts that number to increase to 23,880 incident cases by 2026. - It is estimated that the majority of diagnosed cases were in males in
2017. - The incidence of PTCL is highest among older individuals aged 60+
years. The approved drugs in the PTCL space focus on a wide variety of
targets. These drugs are administered via the intravenous and oral
routes. - The majority of industry-sponsored drugs in active clinical
development for PTCL are in Phase II, with only one drug in Phase III.
Therapies in the pipeline for PTCL focus on a wide variety of targets.
The majority of pipeline drugs in development are administered
intravenously, with a smaller number being tested in oral formulations. - High-impact upcoming events for drugs in the PTCL space comprise
topline Phase II trial results for Darzalex and Zinapar. The overall
likelihood of approval of a Phase I hematologic asset is 10.7%, and
the average probability a drug advances from Phase III is 57.6%.
Drugs, on average, take 8.7 years from Phase I to approval, compared
to 9.2 years in the overall oncology space. - There have been 14 licensing and asset acquisition deals involving
PTCL drugs during 2013-18. The $190m exclusive licensing agreement
signed in October 2017 between Karyopharm and Ono Pharmaceutical for
the development and marketing of Karyopharm’s selinexor and KPT-8602
in South Korea, Hong Kong, Taiwan, Japan, and ASEAN countries was the
largest deal during the period. - The clinical trials distribution across Phase I-IV indicates that the
vast majority of trials for PTCL have been in the early and midphases
of development, with 93% of trials in Phase I-II, and only 7% in Phase
III-IV. - The US has a substantial lead in the number of PTCL clinical trials
globally. The UK leads the major EU markets, while Japan has the top
spot in Asia. - Clinical trial activity in the PTCL space is dominated by completed
trials. Celgene has the highest number of completed clinical trials
for PTCL, with nine trials. - Celgene leads industry sponsors with the highest number of clinical
trials for PTCL, followed by Spectrum Pharmaceuticals.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
Subtypes
TREATMENT
EPIDEMIOLOGY
MARKETED DRUGS
Approvals by country
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
Adcetris for PTCL (October 1, 2018)
Cerdulatinib for PTCL (June 4, 2018)
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
Adcetris Speeds To PTCL Approval With Two-Week Review
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
Onxeo Seeks Partner For Its Expanding Oncology Pipeline
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/o7o429
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Hematology